18 completed, 4 not yet recruiting, 4 recruiting, 4 terminated. 34 Phase 2, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 18, Not yet recruiting 4, Recruiting 4, Terminated 4, Unknown 3, Withdrawn 1 |
| Phase 3 | 4 | Not yet recruiting 2, Recruiting 2 |
Follow Non-squamous Non-small Cell Lung Cancer: new trials by email Literature Review of Non-squamous Non-small Cell Lung Cancer trials Research Report on Non-squamous Non-small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 166 | 2026-11-01 | 2026-10-28 |
| A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure SKB264+SKB118 - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 110 | 2026-10-15 | 2026-10-02 |
| A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC BL-M07D1, Pembrolizumab - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 80 | 2026-02-03 | 2026-03-05 |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi) - Non-Squamous Non-Small Cell Lung Cancer, c-MET | Phase 2 / Phase 3 | Recruiting | AbbVie | 854 | 2025-08-03 | 2026-10-05 |
| Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy JS207, Pemetrexed, Carboplatin or cisplatin - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 78 | 2025-03-30 | 2026-05-18 |
| A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors B1962 - Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Not yet recruiting | Tasly Biopharmaceuticals Co., Ltd. | 120 | 2024-12-01 | 2024-12-09 |
| A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer HS-20117, Aumolertinib - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | Recruiting | Hansoh BioMedical R&D Company | 1080 | 2024-05-28 | 2025-08-01 |
| A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin - Non-squamous Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Shengdi Pharmaceutical Co., Ltd | 401 | 2024-03-01 | 2024-03-28 |
| Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure Serplulimab, Bevacizumab Biosimilar HLX04, Pemetrexed - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 46 | 2023-05-08 | 2024-03-28 |
| Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA Tusamitamab ravtansine - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Terminated | Sanofi | 22 | 2022-06-01 | 2025-08-29 |
| Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed - Non-squamous Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Unknown | Sichuan Cancer Hospital and Research Institute | 20 | 2022-06-01 | 2022-05-27 |
| Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) Durvalumab, Tremelimumab - Squamous Non-small Cell Lung Cancer, Non-Squamous Non-small Cell Lung Cancer | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2018-11-01 | 2022-01-10 | |
| A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases apatinib docetaxel zoledronic, docetaxel zoledronic - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Unknown | Affiliated Hospital of Hebei University | 40 | 2017-07-03 | 2018-01-17 |
| A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer Placebo, RO5490258, bevacizumab [Avastin] - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Genentech, Inc. | 259 | 2012-04-01 | 2016-09-23 |
| A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer Placebo, cisplatin/carboplatin, onartuzumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Genentech, Inc. | 108 | 2012-04-01 | 2016-09-02 |
| A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations erlotinib [Tarceva] - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Hoffmann-La Roche | 6 | 2012-01-01 | 2016-02-02 |
| Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) MEGF0444A, bevacizumab, carboplatin - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Genentech, Inc. | 104 | 2011-06-01 | 2016-11-02 |
| A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy erlotinib [Tarceva] - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Hoffmann-La Roche | 60 | 2011-05-23 | 2018-09-17 |
| A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations Erlotinib - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Hoffmann-La Roche | 208 | 2011-04-30 | 2018-09-12 |
| A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Erlotinib - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Hoffmann-La Roche | 30 | 2011-03-31 | 2018-10-31 |
Showing 20 of 34. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Rectal Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Lung Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Breast Diseases (2) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2)
Erlotinib Hydrochloride (11) · Carboplatin (8) · Pemetrexed (8) · Cisplatin (7) · Bevacizumab (6) · Gemcitabine (3) · Paclitaxel (3) · onartuzumab (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · CP protocol (1) · Docetaxel (1) · Platinum (1) · RG-1507 monoclonal antibody (1) · Standard of Care (1) · aumolertinib (1)
Hoffmann-La Roche (15) · Genentech, Inc. (3) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · AbbVie (1) · Affiliated Hospital of Hebei University (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hansoh BioMedical R&D Company (1) · Henan Cancer Hospital (1) · Peregrine Pharmaceuticals (1) · Providence Health & Services (1) · Sanofi (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Shanghai Shengdi Pharmaceutical Co., Ltd (1) · Sichuan Cancer Hospital and Research Institute (1) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (1)
China (10) · Italy (10) · United States (9) · Spain (8) · France (7) · Germany (6) · United Kingdom (6) · Belgium (5) · Australia (4) · Israel (4) · Poland (4) · Taiwan (4) · Argentina (2) · Bulgaria (2) · Canada (2)
Dingzhi Huang, M.D. (1) · Edward Aten, MD (1) · Ina Rhee, M.D., Ph.D. (1) · Lizza Hendriks, MD (1) · Martin Reck, Pr (1) · Rachel Sanborn, MD (1) · Weihua Wang, Doctor (1) · Yun Fan, M.D. (1)
PMID 22025157, PMID 26720423, PMID 29438092
2008 (3), 2004 (1), 2017 (1)